Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

2 articles

Newest first

Research Article 2022-05-03CC BYFree full text

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.

Natalia Vargas-Herrera, Manuel Fernández-Navarro, Nestor E Cabezudo, Percy Soto-Becerra, Gilmer Solís-Sánchez, Stefan Escobar-Agreda +5 more

BackgroundThe administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and immunogenicity of the "booster" dose in these…

medRxiv medRxiv

Open article record in new tab ↗

Research Article 2021-01-31CC BY-NCFree full text · non-commercial reuse

Impact of age, gender, ethnicity and prior disease status on immunogenicity following administration of a single dose of the BNT162b2 mRNA Covid-19 Vaccine: real-world evidence from Israeli healthcare workers, December-January 2020

Kamal Abu Jabal, Hila Ben-Amram, Karine Beiruti, Yunis Batheesh, Christian Sussan, Salman Zarka +1 more

The Pfizer Covid-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We described immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, gender, ethnicity and prior COVID19 infection. Immunogenicity was similar by gender and ethnicity but decreased with age. Those with prior infection had antibody titres one magnitud…

medRxiv medRxiv

Open article record in new tab ↗